Biomarkers Atlas

The advancement of knowledge is only possible by continuing to search for concrete answers to provide new #targeted, #customised and #effective solutions. Biomarkers Atlas: ???????????????? ????????????????? #WeAreAtlas ?? ?? https://lnkd.in/dia7av3d Umberto Malapelle | Silvia Novello | Giancarlo Troncone | Medica Editoria?

The AIOM | Associazione Italiana di Oncologia Medica annual congress has just ended! As usual, it was a valuable opportunity to take a review of the evolution of the Biomarkers Atlas platform and #app, the approval status of centres, current publications and future study projects. But talking about the value that the project has generated, and continues to generate for the entire oncology #community, here is an in-depth look at the contributions for the year 2023 discussed and presented at some of the most important national and international scientific congresses. #WeAreAtlas Access ?? www.biomarkersatlas.com to consult the atlas of #mutations in genes that take on the role of biomarkers for the clinical classification of cancer patients. Umberto Malapelle | Giancarlo Troncone | Silvia Novello | Medica Editoria

?????????????????? ???????????????????? ?????????????? ?????????????????? ?????? ?????????????????? ??????????????! At Biomarkers Atlas we collaborate to drive scientific progress, transforming knowledge into impactful solutions that improve patient health.?? The following timeline highlights further #scientific contributions for the years 2022-2023: discoveries and results obtained through collaboration between healthcare professionals from the 20 National Institutes of the Atlas #network who share information, expertise and knowledge for the advancement of scientific research.? #WeAreAtlas Umberto Malapelle | Silvia Novello | Giancarlo Troncone | Medica Editoria

Sharing knowledge between experts is the pillar on which scientific progress is based. Together, we continue to look forward, working every day to make our results and discoveries available to all, but above all, to turn them into concrete solutions for everyone's health.? ?? What follows is only a small part of the scientific contribution #BiomarkersAtlas has made to the entire oncology community and beyond in the year 2022.? #WeAreAtlas Umberto Malapelle | Silvia Novello | Giancarlo Troncone |

#BiomarkersAtlas is not only a ??????????????????, ?????????????????? ?????? ???????????????????? ???????? that helps us to better interpret and ???????????????????? ?????? ???????????????????? ?????? ?????????????????????? ???????????????????? ???? ???????? ??????????????????, Atlas is much more and is indispensable for many other reasons.? ?? Let's discover them together with ?? Dott.ssa Sara Pilotto, Associate Professor in Oncology c/o section of Biomedicine of Innovation, Department for Engineering for Medicine of Innovation, Università degli Studi di Verona.? #WeAreAtlas Umberto Malapelle | Giancarlo Troncone | Silvia Novello | Sara Pilotto

To ??????????????????, ??????????????????, and ?????????? as much data and information as possible: an investment for the present and for the future of scientific research.? ?? #BiomarkersAtlas is a project aimed to clinicians, researchers and all healthcare professionals: a platform-database available to all and to all ideas that can flourish. ?? Let's explore what it means to be part of the Atlas #Network?together with ?? Dr. Domenico Galetta, Head of SSD Medical Oncology Thoracic Pathology, Coordinator Pleuro-Pulmonary Oncology Team at IRCCS Oncology Giovanni Paolo II, Bari. #WeAreAtlas Umberto Malapelle | Silvia Novello | Giancarlo Troncone | Domenico Galetta

La seconda giornata di "INTERACTION" ha approfondito ulteriormente la sinergia tra anatomia patologica e oncologia. ?? Abbiamo esaminato come la caratterizzazione molecolare ad ampio spettro possa influenzare significativamente le scelte terapeutiche e la gestione clinica dei pazienti con tumore del polmone. Momenti chiave della giornata: ?? Una visione clinica dell'anatomia patologica presentata da Paolo Graziano. ?? Un'ampia panoramica sulla patologia molecolare predittiva con Umberto Malapelle. ?? Workshop interattivi insieme a Francesco Passiglia, elena guerini rocco, Umberto Malapelle e Paolo Graziano su: ?? il ruolo dei knowledge base database nell’interpretazione delle varianti mutazionali, l’esempio di Biomarkers Atlas; ?? il consenso raggiunto in merito alla refertazione, essenziale per un approccio terapeutico integrato ed efficace; ?? come le procedure analitiche impattano sulle scelte cliniche, navigando il Virtual Lab di 4oncommunity.

#KRAS viral oncogene mutations have been detected in about one third of #NSCLC with p.G12C being the most common pathogenic variant, reported in 12% of overall NSCLC and 39% of KRAS-mutant patients, respectively. After several years of research, the recent development of a new class of small molecules represented a major breakthrough for the treatment of #lungcancer patients. ?? What molecules are we talking about? ?? Discover more in this paper?? https://lnkd.in/dVZy3JZR Umberto Malapelle | Silvia Novello | Maria Lucia Reale | Domenico Galetta | Giulia Pasello | Emilio Bria | Sara Pilotto | Marcello Tiseo | Angelo Delmonte | Rita Chiari | et al..

In an ambitious project like #ATLAS, where the amount of clinical #data is very high and the number of variables is very large and widespread, how important is the role of the #oncologist in ensuring that the data are rigorous, orderly and qualitatively accurate? ?? Let's find out together with Dott.ssa Maria Lucia Reale, Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy.? #WeAreAtlas Umberto Malapelle | Silvia Novello | Giancarlo Troncone | Maria Lucia Reale

#EGFR exon 20 insertions is becoming more and more predictive, due to the approval of different therapeutic approaches and others that are currently under investigation. Thus, despite the low frequency of these alterations, it is crucial their identification in order to avoid leaving any patient behind. Learn more about the topic by reading this Biomarkers Atlas paper produced by an amazing Italian collaborative group working on #predictivebiomarkers in #precisiononcology. ?? ?? https://lnkd.in/dEt-pN5K Umberto Malapelle | Silvia Novello | Giancarlo Troncone | Maria Lucia Reale | Sara Pilotto | Pasquale Pisapia | Domenico Galetta | Francesco Pepe | Diego Cortinovis | Marcello Tiseo | Antonio Passaro | Fabio Pagni | Maria Rita Migliorino | Lorenzo Belluomini